•
Mar 31, 2024

ClearPoint Neuro Q1 2024 Earnings Report

ClearPoint Neuro achieved record revenue and strategic progress.

Key Takeaways

ClearPoint Neuro reported a strong first quarter in 2024, achieving record revenue of $7.6 million, a 41% year-over-year increase. The company saw significant growth in biologics and drug delivery revenue, as well as capital equipment sales, and reduced its operational cash burn.

Reported quarterly revenue of $7.6 million, a 41% year-over-year increase.

Increased biologics and drug delivery revenue to $4.3 million, a 61% year-over-year increase.

Activated eight new hospital customers, a new Company record for a quarter.

Operational cash burn reduced to $3.8 million, a 32% year-over-year decrease.

Total Revenue
$7.64M
Previous year: $5.43M
+40.6%
EPS
-$0.16
Previous year: -$0.23
-30.4%
Gross Margin
59%
Gross Profit
$4.53M
Previous year: $3.2M
+41.3%
Cash and Equivalents
$35.4M
Previous year: $21.8M
+62.4%
Free Cash Flow
-$3.84M
Previous year: -$5.82M
-34.0%
Total Assets
$53.6M
Previous year: $50.2M
+6.7%

ClearPoint Neuro

ClearPoint Neuro

ClearPoint Neuro Revenue by Segment

Forward Guidance

The Company reaffirms its full year 2024 revenue outlook of between $28.0 and $32.0 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income